| Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists |
|
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
| Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care |
|
Transplantation and Cellular Therapy |
Myelodysplastic Syndromes (MDS) |
| Transplantation in patients with lower-risk MDS: a prospective phase 2 trial based on donor availability |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Transplant Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care |
|
Transplantation and Cellular Therapy |
Myelodysplastic Syndromes (MDS) |
| Transfusion Support of Patients with Myelodysplastic Syndromes |
|
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
| Traipsing Through Muddy Waters: A Critical Review of the Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes |
|
Hematology/oncology clinics of North America |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
| TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype |
|
Blood |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
| Towards graft- versus-host disease-free alternative donor transplant platforms for patients with acquired aplastic anemia |
|
Haematologica |
Aplastic Anemia, Graft Versus Host Disease (GVHD) |
| Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
